31 , 11891205.e1113 (2020)
Future research objectives must concentrate on creating prediction algorithms for appropriate receptor targeting ratios, exploring triple-agonist strategies (GLP-1/GIP/glucagon), and determining long-term safety profiles for multi-receptor therapies
These medications, such as Ozempic and Wegovy, have revolutionized the treatment landscape for obesity and type 2 diabetes, yet the journey can be rocky due to these side effects
Underwriters are also getting better at detecting GLP-1 use through: Prescription databases Medical records requests Follow-up health questionnaires What This Means for Your Clients If currently on GLP-1 medications: Expect questions about medication use and duration Be prepared for potentially higher rates despite current health improvements Consider timing of application if they've been stable on medication for an extended period If recently stopped GLP-1 medications: Underwriters may view recent discontinuation as a risk factor Weight regain could further complicate the application process Medical follow-up showing sustained health improvements may help If planning to start GLP-1 medications: Understand that future applications may be affected by medication use Industry Trends to Watch Some forward-thinking insurance companies are exploring partnerships with GLP-1 providers to improve medication adherence
LillyDirect pharmacy: Zepbound injection, Foundayo tablet NovoCare pharmacy: Wegovy injections, Wegovy tablets Each GLP-1 drug is a little different
doi: 10.1016/S0021-9258(18)68261-4 141 GkeRLarsenPJMikkelsenJDSheikhSP
